| Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects (NCT04309734) | Atea Pharmaceuticals, Inc. | 2021-10-01 |
| The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China (NCT04997564) | Peking University First Hospital | 2021-08-01 |
| Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders (NCT04695769) | Helwan University | 2020-11-21 |
| Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access (NCT04614142) | Massachusetts General Hospital | 2020-11-13 |
| Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects (NCT04232514) | Sunshine Lake Pharma Co., Ltd. | 2020-07-15 |
| Cross Sectional Survey on the Burden, Impacts and Causes of Hepatitis C Virus (HCV) Outbreak in South West Region in Burkina Faso (NCT04136405) | ANRS, Emerging Infectious Diseases | 2020-07-14 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (NCT04202952) | Sunshine Lake Pharma Co., Ltd. | 2020-07-06 |
| Study of Telemedicine Stress Management and Lifestyle Group Intervention for HCV Patients (NCT04198584) | University of North Carolina, Chapel Hill | 2020-04-10 |
| The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects (NCT04201275) | Sunshine Lake Pharma Co., Ltd. | 2019-12-18 |
| Metabolic Changes in Chronic HCV Patients Receiving DAAS (NCT04211844) | Ain Shams University | 2019-10-01 |
| Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong (NCT03993925) | The University of Hong Kong | 2019-09-20 |
| An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C (NCT04301882) | Beijing Ditan Hospital | 2019-09-01 |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients (NCT03163849) | Assiut University | 2019-09-01 |
| Monitoring of Hepatitis C Treatment Using Telemedicine - a Clinical Trial in Public Health System in Brazil (NCT04039698) | Hospital de Clinicas de Porto Alegre | 2019-08-23 |
| Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C (NCT04071353) | Beijing Ditan Hospital | 2019-08-01 |
| Frequency of Anxiety and Depression in Chronic Hepatitis C Patients Recieving Direct-Acting Antiviral Agents (NCT03894696) | Assiut University | 2019-08-01 |
| Study of AT-527 in Combination With Daclatasvir in Subjects With Hepatitis C Virus (HCV) Infection (NCT04019717) | Atea Pharmaceuticals, Inc. | 2019-06-20 |
| Changes in Liver Fibrosis, Lipid Profile and Insulin Resistance in HCV Patients Who Received Antiviral Therapy (NCT03612973) | Assiut University | 2019-06-01 |
| Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C) (NCT03887637) | Third Affiliated Hospital, Sun Yat-Sen University | 2019-03-30 |
| The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (NCT03903081) | Sunshine Lake Pharma Co., Ltd. | 2019-03-06 |
| Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation (NCT03723824) | Taichung Veterans General Hospital | 2019-02-14 |
| The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients (NCT03687229) | Assiut University | 2019-01-01 |
| Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis (NCT03693586) | Hospital General de Mexico | 2018-10-19 |
| The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects (NCT03673696) | Sunshine Lake Pharma Co., Ltd. | 2018-09-04 |
| Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL) (NCT03501550) | Cocrystal Pharma, Inc. | 2018-06-26 |
| Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) (NCT03500562) | Bristol-Myers Squibb | 2018-05-08 |
| Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections (NCT03495570) | University College, London | 2018-04-15 |
| Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin (NCT03283176) | Assiut University | 2018-03-01 |
| Re-treatment of HCV Following DAA Failure (NCT03483987) | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 2018-02-10 |
| "Real Life" Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt (NCT03510637) | ANRS, Emerging Infectious Diseases | 2018-01-22 |
| A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China (NCT03430830) | Ascletis Pharmaceuticals Co., Ltd. | 2018-01-15 |
| The Tolerability and Pharmacokinetics Study of Kangdaprevir Sodium Tablet in Healthy Adult Subjects (NCT03811678) | Sunshine Lake Pharma Co., Ltd. | 2018-01-11 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination (NCT03490097) | Ain Shams University | 2017-12-01 |
| A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients (NCT02617615) | Microbio Co Ltd | 2017-12-01 |
| Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection (NCT03098121) | Taoyuan General Hospital | 2017-10-20 |
| 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat' (NCT03088917) | Radboud University Medical Center | 2017-09-27 |
| Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy (NCT03155113) | Azienda Ospedaliero-Universitaria di Parma | 2017-08-30 |
| Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection (NCT04094272) | Kantonsspital Olten | 2017-07-01 |
| Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease (NCT03036852) | Gilead Sciences | 2017-03-22 |
| Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation (NCT03053180) | AbbVie | 2017-03-20 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia (NCT02851069) | AbbVie | 2017-02-23 |
| Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C (NCT02946034) | Massachusetts General Hospital | 2017-02-01 |
| Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C (NCT03022006) | Norte Study Group | 2017-01-15 |
| Eliminate Hepatitis C/EC Partnership Evaluation Protocol (NCT04061551) | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 2016-12-01 |
| Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis (NCT01951209) | David E. Kaplan, MD MSc | 2016-11-17 |
| Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients (NCT03067883) | Ain Shams University | 2016-11-09 |
| Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World (NCT02964091) | Partners in Health | 2016-10-01 |
| Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment (NCT02865369) | Sang Gyune Kim | 2016-09-01 |
| Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania (NCT02807402) | AbbVie | 2016-07-14 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (NCT02803138) | AbbVie | 2016-07-07 |
| Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model (NCT03488485) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2016-06-18 |
| DAA Therapy in Pediatric Patients With Chronic Hepatitis C (NCT03481036) | Post Graduate Institute of Medical Education and Research, Chandigarh | 2016-06-18 |
| Study of Oral Treatments for Hepatitis C (NCT02786537) | University of Florida | 2016-06-01 |
| Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III (NCT03020082) | Ascletis Pharmaceuticals Co., Ltd. | 2016-06-01 |
| Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study (NCT02798315) | AbbVie | 2016-05-25 |
| A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (NCT02738138) | AbbVie | 2016-05-17 |
| Side Effects After Direct-acting Antiviral Treatment (NCT03346941) | Hospices Civils de Lyon | 2016-05-01 |
| Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (NCT02745535) | University of Maryland, Baltimore | 2016-05-01 |
| A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection (NCT02716428) | Trek Therapeutics, PBC | 2016-05-01 |
| A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2) (NCT02692703) | AbbVie | 2016-04-22 |
| Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation (NCT02669940) | AbbVie | 2016-04-15 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C (NCT02725866) | AbbVie | 2016-04-05 |
| A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (NCT03710252) | American Research Corporation | 2016-03-01 |
| Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease (NCT02691728) | Peter J. Ruane, M.D., Inc. | 2016-02-01 |
| The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs (NCT03188276) | Third Affiliated Hospital, Sun Yat-Sen University | 2016-02-01 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (NCT02817594) | AbbVie | 2016-01-20 |
| Long Term Follow-up of Hepatitis C Cured Patients (NCT03246048) | Hospital Universitari Vall d'Hebron Research Institute | 2016-01-01 |
| Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II (NCT03020004) | Ascletis Pharmaceuticals Co., Ltd. | 2016-01-01 |
| The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France (NCT02618928) | AbbVie | 2015-12-15 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (NCT02642432) | AbbVie | 2015-12-07 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) (NCT02615145) | AbbVie | 2015-12-03 |
| Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs (NCT02609893) | Phillip Coffin, MD, MIA | 2015-12-01 |
| A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection (NCT02640157) | AbbVie | 2015-12-01 |
| Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary (NCT02636608) | AbbVie | 2015-11-27 |
| Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C (NCT02640547) | AbbVie | 2015-11-26 |
| The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland (NCT02582671) | AbbVie | 2015-11-05 |
| Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related (NCT03313154) | Azienda Ospedaliero Universitaria di Cagliari | 2015-11-01 |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir (NCT02569710) | Alios Biopharma Inc. | 2015-10-31 |
| Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada (NCT02581189) | AbbVie | 2015-10-13 |
| Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) (NCT02582658) | AbbVie | 2015-10-06 |
| A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection (NCT02604017) | AbbVie | 2015-10-01 |
| A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection (NCT02593162) | Trek Therapeutics, PBC | 2015-10-01 |
| Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy (NCT02638233) | Wilhelminenspital Vienna | 2015-09-01 |
| SR-BI and Antiviral Treatment Response in HCV (NCT02714712) | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 2015-08-01 |
| Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan (NCT03020095) | Ascletis Pharmaceuticals Co., Ltd. | 2015-08-01 |
| A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers (NCT02512562) | Alios Biopharma Inc. | 2015-07-31 |
| The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study (NCT01831037) | University of Arkansas | 2015-07-01 |
| Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults (NCT02476617) | AbbVie | 2015-06-01 |
| Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults (NCT02493855) | AbbVie | 2015-06-01 |
| The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III) (NCT01890200) | TCM Biotech International Corp. | 2015-06-01 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection (NCT02442284) | AbbVie | 2015-05-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy (NCT02446717) | AbbVie | 2015-04-01 |
| Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (NCT02250807) | Janssen R&D Ireland | 2015-01-01 |
| Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells (NCT02545387) | Medical University of Graz | 2015-01-01 |
| Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C) (NCT02439567) | Hospital Universitari Vall d'Hebron Research Institute | 2015-01-01 |
| A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 (NCT02371408) | Pharco Pharmaceuticals | 2015-01-01 |
| First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 (NCT02339207) | Alios Biopharma Inc. | 2014-12-31 |
| The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects (NCT03462173) | Sunshine Lake Pharma Co., Ltd. | 2014-12-03 |
| A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (NCT02219477) | AbbVie | 2014-11-24 |
| Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C (NCT02545335) | Medical University of Graz | 2014-11-01 |